<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788459</url>
  </required_header>
  <id_info>
    <org_study_id>COV-1/2-01</org_study_id>
    <secondary_id>2020-003734-20</secondary_id>
    <nct_id>NCT04788459</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rottapharm Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose&#xD;
      escalation part (Phase 1 study) followed by an open-label single arm (or two-arms,&#xD;
      randomized) dose expansion part (Phase 2 study). The vaccine will be administered by&#xD;
      intramuscular (IM) injection followed by electroporation (EP) applied to the injection site.&#xD;
&#xD;
      The study is aimed at assessing the safety and immunogenicity of COVID-eVax, a DNA&#xD;
      plasmid-based vaccine whose target antigen is a portion of the S protein of SARS-CoV-2 virus&#xD;
      (the Receptor Binding Domain located in the CTD1 of the S1 region of the S protein).&#xD;
&#xD;
      In animal models COVID-eVax was safe and induced high immunological humoral and cellular&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1)</measure>
    <time_frame>Through 7 days post-each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of solicited systemic AEs (for Phase 1)</measure>
    <time_frame>Through 7 days post-each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>White Blood Cell (WBC) levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red Blood Cell (RBC) levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine Transaminase (ALT) levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate Transaminase (AST) levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatine Phosphokinase (CPK) levels (for Phase 1)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>Geometric Mean Titer (GMT) and Geometric Mean Fold Rise (GMFR) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 neutralizing antibody titer (for Phase 2)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>GMT and GMFR from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>Interferon-gamma (IFN-γ) ELISpot</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who seroconverted (for Phase 2)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 1)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>GMT and GMFR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 neutralizing antibody titer (for Phase 1)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>GMT and GMFR from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 1)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
    <description>Interferon-gamma (IFN-γ) ELISpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who seroconverted (for Phase 1)</measure>
    <time_frame>through 4 weeks post-last vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited AEs (for Phase 1)</measure>
    <time_frame>through study completion (6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of solicited local AEs at the injection site (for Phase 2)</measure>
    <time_frame>Through 7 days post-each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of solicited systemic AEs (for Phase 2)</measure>
    <time_frame>Through 7 days post-each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited AEs (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cell (WBC) levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Transaminase (ALT) levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Transaminase (AST) levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine Phosphokinase (CPK) levels (for Phase 2)</measure>
    <time_frame>through 4 weeks post-each vaccination</time_frame>
    <description>Change from baseline at specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited AEs (for Phase 2)</measure>
    <time_frame>through study completion (6 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>COVID-19</condition>
  <condition>Protection Against COVID-19 and Infections With SARS-CoV- 2</condition>
  <condition>COVID-19 Immunisation</condition>
  <arm_group>
    <arm_group_label>0.5 mg PB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 1 mg&#xD;
IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg PB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 2 mg&#xD;
IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg PB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg PB (Prime-Boost, 4 weeks apart) - Total dose: 4 mg&#xD;
IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg P (Prime) - Total dose: 2 mg&#xD;
IM injection + electroporation by IGEA Cliniporator® and EPSGun, on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-eVax</intervention_name>
    <description>Plasmid DNA Vaccine for COVID-19</description>
    <arm_group_label>0.5 mg PB</arm_group_label>
    <arm_group_label>1 mg PB</arm_group_label>
    <arm_group_label>2 mg P</arm_group_label>
    <arm_group_label>2 mg PB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cliniporator® and EPSGun</intervention_name>
    <description>IGEA Electroporation Device</description>
    <arm_group_label>0.5 mg PB</arm_group_label>
    <arm_group_label>1 mg PB</arm_group_label>
    <arm_group_label>2 mg P</arm_group_label>
    <arm_group_label>2 mg PB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent obtained before undergoing any study-specific&#xD;
             procedure&#xD;
&#xD;
          2. Healthy male or female aged ≥18 and ≤ 65 years&#xD;
&#xD;
          3. Body Mass Index &gt;18.5 and ≤30 kg/m2&#xD;
&#xD;
          4. Vital signs within the following values or ranges:&#xD;
&#xD;
               1. Body temperature ≤ 37,5 °C&#xD;
&#xD;
               2. Pulse frequency ≥51 and ≤100 beats per minute&#xD;
&#xD;
               3. Diastolic BP ≥60 mmHg, ≤ 90 mmHg&#xD;
&#xD;
               4. Systolic BP ≥ 90 mmHg, ≤ 140 mmHg&#xD;
&#xD;
               5. Respiratory rate ≥ 12 breaths per minute, ≤ 16 breaths per minute&#xD;
&#xD;
          5. ECG at screening normal or with no clinically significant findings (pre-excitation&#xD;
             syndromes, e.g., Wolff-Parkinson-White syndrome are absolute exclusion criteria)&#xD;
&#xD;
          6. Laboratory examinations within normal reference range or with no clinically&#xD;
             significant abnormalities&#xD;
&#xD;
          7. Absence of any respiratory and flu-like symptoms&#xD;
&#xD;
          8. Non-pregnant women of childbearing potential, willing to practice a highly effective&#xD;
             method of contraception from enrolment up to study completion or at least 90 days&#xD;
             after the last vaccination in case of withdrawal&#xD;
&#xD;
          9. For sexually active men with a female partner of childbearing potential, willingness&#xD;
             to use a condom and to refrain from donating sperm from enrolment up to study&#xD;
             completion or at least 90 days after the last vaccination in case of withdrawal&#xD;
&#xD;
         10. Agreement to refrain from blood donation during the course of the study&#xD;
&#xD;
         11. Able and willing to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of confirmed infection with SARS-CoV-2, by positive nasopharyngeal swab or by&#xD;
             positive serological test for SARS-CoV-2 antibodies&#xD;
&#xD;
          2. Positive serological test for SARS-CoV-2 antibodies at screening&#xD;
&#xD;
          3. Subjects at high risk of SARS-CoV-2 infection prior or during the trial, including:&#xD;
&#xD;
               1. subjects with any known exposure in the 4 weeks before enrolment&#xD;
&#xD;
               2. close contacts of suspected or confirmed COVID-19 or SARS-CoV-2 infection cases&#xD;
&#xD;
               3. subjects quarantined for any reason&#xD;
&#xD;
               4. frontline healthcare professionals working in Emergency departments, ICU and&#xD;
                  other higher risk healthcare areas&#xD;
&#xD;
          4. Positive serological tests for:&#xD;
&#xD;
               1. Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               2. Hepatitis C antibodies&#xD;
&#xD;
               3. Human Immunodeficiency Virus (HIV) antibodies&#xD;
&#xD;
          5. Subjects with any of the following specific contraindications, even in medical&#xD;
             history:&#xD;
&#xD;
               1. Type 2 diabetes or glucose intolerance, even if controlled&#xD;
&#xD;
               2. Hypertension, even if controlled&#xD;
&#xD;
               3. chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
               4. Any cardiac disease, even if not evident at ECG&#xD;
&#xD;
               5. Pacemaker&#xD;
&#xD;
          6. Use of any investigational drugs/treatments, or enrolment in a clinical trial during&#xD;
             the 6 months preceding screening&#xD;
&#xD;
          7. Prior administration of any vaccine in the 2 weeks preceding screening&#xD;
&#xD;
          8. Administration of any monoclonal or polyclonal antibody product within 4 weeks&#xD;
             preceding screening&#xD;
&#xD;
          9. Administration of any blood product within 3 months of screening&#xD;
&#xD;
         10. Current or prior administration, within the 6 months preceding screening, of&#xD;
             immunosuppressants (inhaled, topical skin and/or eye drop-containing corticosteroids;&#xD;
             a short course of corticosteroids, defined as ≤20 mg/day prednisone or equivalent for&#xD;
             10 days, and low-dose methotrexate are allowed until 4 weeks prior to screening)&#xD;
&#xD;
         11. Any prior major surgery or any chemo- or radiation therapy within 5 years of screening&#xD;
&#xD;
         12. Current or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection, asplenia, recurrent severe infections&#xD;
&#xD;
         13. Active, known, or suspected autoimmune disease (except mild psoriasis, well-controlled&#xD;
             autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring&#xD;
             immunosuppressive or immunomodulatory therapy)&#xD;
&#xD;
         14. Bleeding disorders (e.g. coagulopathy or platelet disorder or coagulation factor&#xD;
             deficiency) or prior history of significant bleeding or bruising following IM&#xD;
             injections or venipuncture&#xD;
&#xD;
         15. History of seizures or mental illness&#xD;
&#xD;
         16. History of allergy to vaccines or of severe allergic reaction of any kind&#xD;
&#xD;
         17. Metal implants within 20 cm of the planned site(s) of injection&#xD;
&#xD;
         18. Presence of keloid scar formation or hypertrophic scar, or other clinically&#xD;
             significant medical condition at the planned site(s) of injection&#xD;
&#xD;
         19. Any abnormality or permanent body art (e.g. tattoos) that would interfere with the&#xD;
             ability to observe local reactions at the injection site in the deltoid area&#xD;
&#xD;
         20. History of alcohol or drug abuse during the 12 months preceding the screening&#xD;
&#xD;
         21. Pregnancy (i.e. positive pregnancy test) or willingness/intention to become pregnant&#xD;
             during the study&#xD;
&#xD;
         22. Breastfeeding&#xD;
&#xD;
         23. Any other clinically relevant disease and condition that, in the opinion of the&#xD;
             Investigator, may jeopardize efficacy or safety assessments or may compromise the&#xD;
             subject's safety during trial participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luigi Aurisicchio</last_name>
    <phone>+39 06 50576077</phone>
    <email>aurisicchio@takisbiotech.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Brambilla</last_name>
    <phone>+390399066055</phone>
    <email>nadia.brambilla@rottapharmbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Bonfanti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo A Ascierto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>INMI Lazzaro Spallanzani</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simone Lanini, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infections Viral</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Vaccine</keyword>
  <keyword>SARS-COV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

